CXCR4 and neoplasm: Apart from constituting an HSC mobilising agent, both preclinical [123] and clinical studies [146] have suggested that AMD3100 and other CXCR4 antagonists exhibit anticancer activity, inhibiting tumor growth and metastasis as well as counteracting an immunosuppressive intratumoral microenvironment (Figure 4).